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ABSTRACT 
Introduction: The treatment of neurological disease, such as brain cancer or neurodegenerative diseases, is one of 
the most difficult challenges in medicine. The major limitation in this therapy is caused by asthenia of some drugs 
injected to the blood vessel to reach the main tissue of brain. There are three substrate obstacles that adjust molecular 
exchange in junction between blood and neurotic tissue or its steep spaces: the brain endothelium which makes 
blood-brain barrier (BBB), the arachnoids epithelium which makes intermediate substrate of meninges and the 
choroid plexus epithelium, which secretes cerebrospinal fluid (CSF). 
Methods: In recent years, some significant researches showed that magnetic nanoparticles (through conjugation of 
iron oxide NPs with hydrophilic polymer coatings of dextran) can be administered for impressive systemic and 
territorial transfer of therapeutics to the CNS. Nanoparticles also have the potential to revolutionize conventional 
imaging techniques. Conventional epitomize condition lack the association of high delicacy and high spatial 
precision required for molecular imaging. 
Results: Magnetic Resonance Imaging (MRI) has high resolution, but lacks sensitivity to molecular signals, while 
high sensitivity nuclear medicine modalities such as Individual photon ejaculation calculated tomography and 
position emission tomography (PET) provide superb sensitivity, at the cost of reduced spatial resolution. Using 
nanoparticles in some conditions such as MRI can amazingly enhance delicacy, presenting the potential for high 
resolution molecular imaging. MRI has high spatial resolution, is non-invasive in nature and offers multiplanar 
tomographic capabilities. Nanoparticles can be managed to have magnetized specifications that can be acquired by 
MRI at low condensations and at the same time include lingads which target specific molecules. Iron oxide 
nanoparticles have been widely researched for MRI, as there are several types, namely magnetite (Fe3O4) and 
hematite (α-Fe2O3), among which magnetite is very promising, because of its proven biocompatibility. For 
molecular imaging purposes, superparamagnetic iron oxide nanoparticles (SPIONs) need to bind to a range of drugs, 
proteins, enzymes, antibodies, or other molecular targets. In conclusion, using magnetized nanoparticles as a drug 
delivering system is still determined by its biocompatibility and optional aiming to the favorable cell or tissue under 
the guidance of external magnetic field (MRI scanner).  
Conclusion: Advances in current technologies and the expansion of magnetized nanoparticles as medicine transfer 
device to transfer medicine to tumor hypoxic zones have fast tracked in the past decade and led to the development 
of various magnetic nanoformulations such as liposomes, metallic, and polymeric nanoparticles. This technology 
will not only minimize invasive methods, nut also decrease side effects to intact fiber which are two primary concerns 
in conventional cancer therapies. The field of magnetic drug delivery is still at infancy, and combination of better 
magnetized medicine transfer device and association of multifunctional ligands are being continuously investigated 
so as to carry it from the bench-top to the clinic. Until Then the worries about the omission and long term toxicity 
remain barriers to clinical entry. 
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1. INTRODUCTION  
Due to the instant need for ameliorate biomarkers and treatment for psychiatric, developmental, ulcerous, 
inflammatory, infectious and degenerative central nervous system (CNS) disorders, interest in nanoneuromedicine 
has increased amazingly, inflammatory, infectious and degenerative central nervous system (CNS) disorders 
(Rahmani Tanha, 2016; Fatehi, 2016; Gendelman, 2014). These, in whole or in part are a considerable societal 
responsibility due to increase in numbers of affected people and in illness intensity. Lost efficiency of a patient and 
his or her caregiver, and the fiscal and emotional responsibility cannot be overestimated. Necessity of better health 
care, therapy and diagnostics is essential. One of the ways to get this target is called nanotechnology. Indeed, new 
progresses of health care enables nanotechnologies and nanomedicine scope from biomarker detection containing 
neuroimaging to therapeutic applications for corruptive, degenerative and zymotic disturbance of the CNS (Fatehi, 
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2016; Jahangiri, 2016). This publication centralize on the running and subsequent potential of the field to positively 
modify clinical results many CNS disorders remain unresolved clinical problems. In some instances, medicine factors 
simply cannot pass the blood brain barrier (BBB) into the CNS (Pardridge, 2005). The appearance of nanomedicines 
can increase the transfer of biologically active molecules for aimed treatment and imaging. The field of 
nanoneuromedicine suggest real chances to harness unique therapeutic approaches to address diseases of the CNS 
where often few options exist, because of the enormous potential of the field. In addition to improved therapies, 
novel, more secure and more sensitive specific imaging conditions as well as better diagnostics for finding illness 
are instantly needed CNS disorders, due to infection, trauma or degenerative disorders; represent a significant societal 
burden with parallel broad unmet needs. In many and some cases, prevalent therapy are simply insufficient to modify 
illness progression or even improve signs of brain injury or degeneration. significant turbulency abound and are 
correlated with deliver of therapeutic or imaging opposition factors across the BBB into the CNS and hold the ability 
to get aimed transfer to proper brain or spinal cord subregions. 
Nanomedicines can facilitate solutions to such problems. This case and relevant enabling technologies can 
enhance drug – drug interplay, simplify improving immunomodulation, enable pathogen rasure and ameliorate CNS 
transfer of biologically active molecules. Included are multifunctional therapeutic, imaging and diagnostic devices 
currently referred to as theranostics. 
However, limitations for improved drug delivery to the CNS are not trivial, including the potential for 
secondary toxicities. Thus, any new formulation must balance a drug therapeutic index. This highlights a quite 
diverse and multifaceted field of research in biomarker discovery, bioimaging and theranostic (Gharib Salehi, 2016). 
If successful, therapies to address neurodegenerative, immune and infectious diseases of the CNS could be realized 
and more options would be available for human use (Ghannad, 2016). In this text, nanotechnology-based methods 
have reached great interest as a gadget in attempt to ameliorate the effectiveness of the imaging of CNS functions 
and disease states as well as to advance neurosurgical practice. Magnetic resonance imaging (MRI) has emerged as 
the most important tool in the diagnosis of brain disorders (Fatehi, 2016). Nanoparticles containing iron, gadolinium 
and manganese were studied extensively as contrast agents. Among them SPIONs have garnered interest due to their 
large surface area, magnetic properties and low toxicity. The BBB shows an impassable barrier for most medicines 
containing neurological drugs cytostatics antibiotics, etc. One efficient possibility to deliver drugs including peptides 
and even macromolecules across this barrier is the employment of polymeric nanoparticles. This possibility was 
recently summarized in a short review in this journal. Unfortunately, previous reviews frequently cite similar 
references and highlight similar points, often for studies that are repetitive or incremental over time. Focus on 
amazingly necessary pharmological effects attained with nanoparticles based transfer as well as perusal regarding 
mechanisms of nanoparticle intercede drug delicery are not often analyzed (Arruebo, 2007).  
Mechanism of nanoparticle-mediated uptake of drugs into the brain: About eight possibilities exist for the 
mechanism of uptake of nanoparticles and of bound drugs into the brain including: an enhanced support of the 
nanoparticles in the brain blood arteriole combined with a sorption to the arteriole septum. This could make a higher 
condensation incline that would enhance the delivery among the indothelial cell layer and as a consequence increase 
the transfer to the brain. The polysorbate 80 used as the covering factor could prevent the current system, particularly 
P-glycoprotein (Pgp) that general toxic effect on the brain vasculature. A general surfactant result determined by the 
solubilization of the endothelial cell velum lipids that would lead to velum fluidization and to enhanced drug 
permeability across the BBB. Opening of the tight junctions between the brain blood vessel endothelial cells. The 
medicine could then infiltrate through the firm linkage in free form or altogether with the nanoparticles in closed 
form.6.endocytosis by the endothelial cells pursued by the extrication of the medicines within these cells and transfer 
to the brain. Transcytosis through the endothelial cell layer. As discussed in detail in a recent review, the nanoparticle 
intercede delivery among the BBB seems to happen by endocytosis of the particles by the brain arteriole endothelial 
cells after intravenous infusion followed by nanoparticle transcytosis across these cells. Earlier reviews  already 
pointed out that mechanisms 1–6 appear to be of no major relevance: Making high medicine condensation incline by 
subordination of nanoparticles to the inner level of the blood arteriole septum (mechanism 1) would not be enough 
for an effective and pharmacologically relevant drug transport across the endothelial cell layer since the diffusing 
drug still would have been subjected to the highly efficient efflux transporters such as Pgp in the luminal membranes 
of these cells.  
These current deliveries also cannot be cloged by the tendance of the 1% polysorbate 80 in the perfused 
nanoparticle pendency because the pre-injection of polysorbate 80-coated empty nanoparticles 5 or 30 min before 
injection of a dalargin solution did not induce any pharmacological effects. If current transporter dissuasion would 
have been the underlying mechanism, these transporters would have been inactivated by the polysorbate limited to 
the empty nanoparticles which then would have enabled the drug flux across the endothelial cells. The fact that pre-
injection of polysorbate-coated empty nanoparticles did not achieve such a transport of drug in solution into the brain 
also refutes mechanisms and permeabilization of the BBB by toxic effects (mechanism 3) or by membrane 
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solubilization caused by the surfactant (mechanism 4) as suggested by Olivier and Calvo, also opening of the tight 
junctions (mechanism 5). This conclusion was further substantiated by electron microscopic studies, histological 
investigations, and toxicological experiments, which did not reveal any toxic effects at therapeutic levels. 
Additionally, a surfacetant induced permeability enhancement Seems to be improbable as no pharmacological 
replications seen after infusion of dalargin nanoparticles covered with other surfactants such aspoloxamers, 
poloxamine, Cremophor, and polyoxyethylene-laurylether.  
The opinion that toxicity is not the mechanism for the nanoparticle-mediated drug transport across the BBB 
further was corroborated by the experiments of San, and of Koziara, Moreover, the electron microscopic studies by 
Zensi and by Kreuter, showed that the tight junctions (mechanism 5) did not open after intravenous administration 
of the nanoparticles. The latter result also is supported by the findings that no major increase in the inulin spaces was 
observable in rat brain perfusion experiments. Such an inauguration of the BBB could be attained for example by 
injection of hyperosmotic solutions and would enhance the inulin areas by a factor of 10-20. Consequently, 
mechanisms 6 and 7, endocytosis followed by transcytosis, are the underlying mechanisms for the transport of drugs 
across the BBB into the brain. In vitro perusal formerly clearly showed the endocytosis uptake of polysorbate 80 or 
poloxamer 188-covered nanoparticles into many primitive endothelial cells as well as into cell lines including mice 
and rat endothelial cell lines as well as primary bovine, porcine, and human endothelial cells. Similarly, an in vitro 
uptake also was observed into neurons and glioblastoma cell lines including A172 human glioblastoma cells 
(Kreuter, 2004).  
To circumvent the BBB for the delivery of drugs to the central CNS, various strategies have been expanded 
such as the cutting of the BBB, chemical adjustment of the medicines to simplify velum penetrance and carrier or 
receptor-mediated medicine transfer. Further variant itinerary overrule the blood circulation altogether. For example, 
drugs can be delivered directly from nose to brain or delivered by intraventricular infusion. However, all these 
methods have limitations such as poor efficacy or invasivity. Thus, one of the major challenges of pharmaceutical 
research is to develop strategies for effective delivery of drugs to the CNS. To achieve this, an emerging approach is 
the use of nano-sized vectors such as liposomes and polymeric nanoparticles (NPs). Particularly, engineered NPs 
could take benefit of different directions for crossing the BBB, such as endocytosis or trancytosis. As shown in 
previous studies, we applied this approach by modifying Polylactide-co-glycolide (PLGA) NPs with a glycopeptide 
(g7) to make nanosystems (g7-NPS) that can enter the brain. Studies done in histological, biodistribution and 
pharmacological subjects have shown that g7-NPs cross the BBB at a high level following several modes of 
administration. Additionally, G7-NPs were found to educe endocytotic directions, both to cross the BBB endotheliul 
in vivo and to enter neurons or glial cells in vitro. in the attached paper (part 1), we focused on some other aspects, 
such as dose – time dependent accumulation of g7-NPs, tropism to specific brain regions and cell subpopulations 
after BBB crossing and constitution of relationship between in vivo and  in vitro demodulations on the uptake 
mechanisms in neurons. Despite the findings gained on these topics, some subjects are still to be focused in depth to 
show an obvious picture of NP uptake, dynamics, deliver and trafficking inside the CNS. in particular, we have 
considered neuronal tendency the possibility of cell targeting using antibody (Ab) modified NPs, the possible 
transport of NPs from cell to cell and the dynamics of intercellular NP  trafficking. In vivo, most cells can be found 
organized as specialized tissues. Within these functional assemblies, cells are able to perform cell to cell 
communication including the transport of intracellular components to organize physiological processes. Within the 
brain, neurons are closely surrounded by glial cells, leaving only a minimal amount of extracellular space. Thus, this 
part II study aims to evaluate the mechanisms of a possible intercellular transport of g7-NPs from cell to cell besides 
their transport within the extracellular fluid after crossing the BBB endothelium (Kreuter, 2002). 
The CNS is composed of a dense network of neurons and glial cells that are highly interconnected. Thus, 
since these cells are not just a loose accumulation, but an organized tissue, cell-to-cell communication is an important 
factor for maintaining a functional organization. However, besides pairing of brain cells via gap-junctions, some 
other mechanisms may exist that can deliver internal as well as external cell components. Seong Deok Kong, have 
focused on the characterization of delivery of SPION to the brain parenchyma of normal mice with intact BBB. First, 
they demonstrate the delivery of SPIONs To the brain administrated by and external magnetic scope with minimal 
neurotoxicity. Second we determine obvious BBB. First they show the transportation of SPIONs to the brain 
administrated by an external magnetic scope with minimal neurotoxicity. Second, they show obvious BBB passing 
and extravasation of SPIONs induced by external magnetic force using cellular level high-resolution imaging 
analysis in vivo. Third, they show the transfer of nanoparticles in the CNS passing the sound BBB. their article 
instate the valency for the adjustment of CNS dispensation of SPIONs with the application of an external magnetic 
scope, showing passing of the BBB and accumulation in the perivascular space with no apparent toxicity, which can 
be beneficial for treatments of CNS diseases (Kreuter, 2001). They have planned and expanded fluorscent SPIONs 
and showed their potency in vivo to access the brain parenchyma by passing the normal BBB under the adjustment 
of an external magnetic scope. While the mechanism of BBB passing subsist unknown, their data indicate that the 
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endothelial membrane is capable of MNP uptake with kinetics that is consistent with the in vivo model. Their AFM 
results demonstrate that these SPIONs are spherical in shape and their average diameter is 124nm, which provide 
enough uptake by human brain endothelial cells. The fluorescence of the SPIONs enables their direct tracking and 
localization within specific vascular niches in the brain. Furthermore, the increased magnetic exclusivity and their 
replication to an external magnetic scope to simplify their extravasation and / or amplitude in the brain parenchyma 
support the idea of using similarly configured, medicine – containing magneticnanocapsules to deliver CNS drugs 
across an intact BBB. They demonstrate in this study the increased sensitivity to a magnetic field of engineered 
SPIONs compared to standard magnetic nanoparticles, and explore the capacity to use such SPIONs to access the 
brain parenchyma. They have focused on delivery across the intact BBB. Recent studies also demonstrate the usage 
of external magnetic field to facilitate the delivery of SPIONs across the BBB. In addition to these reports, their 
research demonstrates BBB translocation of SPIONs with higher resolution confocal analysis to pinpoint the 
extravasation of SPIONs in reference to the vasculature, which is supported by our histological analysis. Furthermore 
unlike in vitro BBB cell culture patterns with some restrictions, our in vivo pattern is more appropriate to discuss the 
multi – cellular intricate nature of BBB and pharmaco-distribution of SPIONs. Moreover, our information 
demonstrate that magnet – mediated transfer of SPIONs can happen in normal brain parenchyma without any 
vascular sprinkle as showed with the TRITC – 70 kDa dextran.  
The internalization of SPIONs observed by the AFM imaging indicates that endocytosis or a non-specific 
membrane-mediated uptake of the SPIONs occurs, the mechanism underlying such uptake is unclear and beyond the 
scope of this study. Nevertheless, the decretive result of these studies is that MNP uptake into the brain does not 
seems to need a main infraction of the endothelial obstacle or change in BBB impeccability. Based on the valency 
to load such MNCs with medicines and the cell biological analysis with respect to BBB integrity, these SPIONs are 
ideal candidates to examine their relevance in translational models (Hernot, 2008). This is due to the significant 
challenge faced by industry and academics in seeking effective drug therapies for the increasing incidence of brain 
disease associated with an ageing population. In this review, we looked at the barrier issue from a biological and 
pathological perspective to provide a better insight to the challenges and opportunities associated with the BBB. We 
need to remind ourselves that we are developing drug delivery systems which ultimately will transport a drug to a 
diseased brain, not a healthy one. The delivery system, including the targeting ligands should be designed based on 
knowledge of the diseased BBB. To successfully target the brain, the selectivity of a BBB receptor is extremely 
critical. This means, ideally, the receptor should be brain specific, or at least, preferentially expressed at the BBB. 
Unfortunately almost all the receptors are nearly non-specific as shown by percentage dose reached the brain 
compared to that reached by the liver, spleen or lung. We believe that the reason for this high level of targeting is the 
design of the delivery system that is based on the pathological condition of the BBB and the fact that the system was 
tested on a diseased model.  
The targeting effect was greatly enhanced further by its combination with the guidance of an external 
magnetic field. In contrast, while RMT worked alone, the best brain targeting, as far as authors are aware, was 
achieved by g7 molecule which was characterized as a high but short lived targeting (14% at peak). Unfortunately 
the majority only achieved 1–4% as a result of poor selectivity and low BBB permeability. Although the amount 
reaching the brain may be sufficient for a therapeutic effect, the loss of 96–99% is huge from the cost point of view, 
in addition to the potential side effects and toxicity that can be caused by 96% of drugs. Jones and Shusta suggest 
the solution may be in combinatory antibody library technology which allows the development of BBB-specific 
RMT. Tosi, showed that the application of double targeting ligands can provide added targeting benefit. These 
nanoparticles containing a fluorophore within have been engineered for direct tracking and measurement of the 
position of SPIONs, which also allow cellular-level high-resolution imaging analysis such as confocal microscopy 
(Kaittanis, 2007). Applied magnetic field facilitated the extravasation and/ or accumulation of these magnetic 
nanoparticles in the brain parenchyma. Similarly configured, but drug-containing magnetic nanocapsules can be 
utilized for BBB crossing and treatment of various CNS diseases. Use of multiple targeting ligands developed with 
consideration of the pathological conditions of the disease will maximize success. Ideally the treatment for a brain 
disease should be constantly monitored and modulated (Kennedy, 2011).  
2. CONCLUSIONS 
The idea of using magnetic or bubble filled and drug-loaded nanocarriers, in combination with MRI and 
ultrasound, may provide a solution for achieving both the diagnosis and treatment purposes (Chen, 2012). In 
conclusion, therefore, is to take the multidiscipline approach with innovative ideas to ultimately achieve the goal of 
delivering both diagnosis and drug therapy, selectively and efficiently, across the BBB. Our final conclusion is that 
any brain-targeted delivery systems must be assessed for their safety, risk and benefit for patients. Currently the 
safety issue has been largely overlooked during the research stage, yet this issue will become critical when the drug 
to be delivered is for a long term therapy. It is extremely important that any delivery systems developed should have 
no significant impact, short or long term, on the functions of the brain. The translation of NPs in clinical use for 
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therapeutic and diagnostics applications looks promising amidst the recent developments (Bohmer, 2009). The field 
of nano-pharmaceuticals is an emerging area of great medicinal interest, which aims at developing novel engineered 
nanoparticles for pharmaceutical applications and show great promise with varied range of usages such as in 
vaccination cell treatment and gene therapy. For example nanoparticle - based medicines attaining significant interest 
in pharmaceutical industry and already in clinical operation are liposomaldoxorubicin and albumin conjugate 
paclitaxel. In addition, many other NP based diagnostic and therapeutic agents are in clinical trials, and future looks 
promising for the fast growing field of nano-diagnostics. Moreover, further improvisations are needed to increase 
the translation of NP formulations from bench to clinics. 
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